الأحد, مايو 25, 2025
  • Login
Ambassador Newspaper
  • الرئيسية
  • جريدة السفير
  • من نحن
  • الأتصال بنا
  • لايف ستايل
    • عراقيات
    • تكنولوجيا
    • مقالات
    • عالم الصحة
    • حول العالم
    • السياسة
    • كلمة العدد
    • ثقافة و فن
    • أخبار العالم
    • منوعة
  • Lifestyle
    • Culture and Art
    • WORLD NEWS
    • Health
    • Iraqi News
    • Organization News
    • Canadian News
  • EN
  • AR
No Result
View All Result
  • الرئيسية
  • جريدة السفير
  • من نحن
  • الأتصال بنا
  • لايف ستايل
    • عراقيات
    • تكنولوجيا
    • مقالات
    • عالم الصحة
    • حول العالم
    • السياسة
    • كلمة العدد
    • ثقافة و فن
    • أخبار العالم
    • منوعة
  • Lifestyle
    • Culture and Art
    • WORLD NEWS
    • Health
    • Iraqi News
    • Organization News
    • Canadian News
  • EN
  • AR
No Result
View All Result
Ambassador Newspaper
No Result
View All Result
Home English

Alzheimer’s drug slowed cognitive decline overall in trial, but with major side effects for some

Duha Faris Al-Serdar by Duha Faris Al-Serdar
ديسمبر 1, 2022
in English, Health
0
Alzheimer’s drug slowed cognitive decline overall in trial, but with major side effects for some
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Alzheimer’s Association says data shows drug could be beneficial to those in earliest stages of disease

An experimental drug for Alzheimer’s disease from Eisai and Biogen slowed cognitive decline in a closely watched trial, but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday

The drug, lecanemab, was associated with a type of brain swelling in 12.6 per cent of trial patients, a side effect previously seen with similar drugs. Fourteen per cent of patients had microhemorrhages in the brain — a symptom linked to two recent deaths of people receiving lecanemab in a follow-on study — and five patients suffered macrohemorrhages

The companies said in September that the 18-month trial, which enrolled nearly 1,800 participants with early-stage Alzheimer’s, found that treatment with lecanemab reduced the rate of decline on a clinical dementia scale (CDR-SB) by 27 per cent compared to a placebo

All of these amyloid-lowering drugs carry a risk for increased brain hemorrhage, said Dr. Ronald Petersen of the Mayo Clinic in Rochester, MinnesotaI think the primary outcomes, the secondary outcomes, the amyloid-lowering is pretty impressive

The Alzheimer’s Association said the data confirms the drug can meaningfully change the course of the disease for people in the earliest stages of Alzheimer’s disease, and called on U.S. regulators to approve the company’s application for accelerated approval

Little benefit for patients with genetic variants

The trial showed no benefit on the CDR-SB measure for some patients with a genetic risk of developing the mind-wasting disease

About 16 per cent of participants had two copies (homozygous) of the APOE4 gene variant known to raise the risk of developing Alzheimer’s, 53 per cent had one copy of the gene (heterozygous) and 31 per cent were non-carriers

For that small group of homozygous patients, when it comes to CDR-SB, we don’t see a signal favouring lecanemab, said Ivan Cheung, Eisai’s U.S. chairman, in an interview. He suggested that could be because homozygous study patients who were given a placebo fared better than expected

The APOE4 carriers did show improvement on the trial’s secondary goals, including other measures of cognition and daily function. Overall, lecanemab patients benefited by 23 per cent to 37 per cent compared with a placebo on these secondary trial goals

I believe it’s an important benefit that will justify full approval. But of course, we want a bigger benefit, said Dr. Paul Aisen, director of the University of Southern California Alzheimer’s Therapeutic Research Institute and a co-author of the study published in the New England Journal of Medicine (new window). He said lecanemab is likely to provide greater benefit if given earlier in the disease, “before you’ve accumulated enough irreversible damage to be causing symptoms”

Detailed data from the study were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco

Eisai, based out of Tokyo, believes the trial results prove a longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer’s can delay its advance

At 18 months, 68 per cent of trial participants treated with lecanemab had amyloid clearance, Eisai said

Two deaths — both from brain hemorrhages — have been reported among participants in a trial extension. They involved a 65-year-old woman who received a type of medicine known as tissue plasminogen activator to clear blood clots after suffering a stroke and an 87-year-old who was on the blood thinner Eliquis

Eisai said it believes the two deaths cannot be attributed to lecanemab

Regulatory push in the coming months

Cheung said Eisai has protocols in place for monitoring brain swelling and sees no need for restrictions on which patients might be eligible for lecanemab treatment

Dr. Howard Fillit, chief science officer at the Alzheimer’s Drug Discovery Foundation, said doctors always balance the benefits and risks of therapies. Currently, I would hesitate to give this drug to someone on blood thinners, he said

The U.S. Food and Drug Administration is slated to decide by Jan. 6 whether to approve lecanemab under its accelerated review program, which requires proof that a drug can impact a biomarker associated with a disease, such as reduction of amyloid beta in the brain

Regardless of that decision, Cheung said Eisai plans to soon file for standard FDA approval of the drug and will also seek approval in Europe and Japan

DEBATING THE RISKS, BENEFITS OF A CONTROVERSIAL ALZHEIMER DRUG

1 year agoDuration6:02There’s debate over whether Canada should follow the U.S.’s lead and approve a controversial drug to treat Alzheimer’s, despite concerns Aducanumab isn’t effective and can be harmful. But the uncertainty isn’t stopping some patients from wanting to try the medication

In a contentious move last year, the FDA approved the first amyloid-targeting drug, Aduhelm from Massachusetts-based Biogen, despite lack of evidence of better patient outcomes. Insurers and many doctors have hesitated to prescribe the pricey drug — another reason experts have anxiously awaited word of how well the newer lecanemab may work

If the FDA approves lecanemab, patients and their families will need a voice in deciding whether it’s worth the hassle of IV infusions and the risk of side-effects for the chance of at least some delay in progression, Petersen said

I don’t think we’re going to stop the disease in its tracks with just amyloid-targeting drugs, he added, saying it will take a combination of medications that target additional Alzheimer’s culprits

Researchers are preparing to test lecanemab with other experimental drugs, and how it works in high-risk people before they show the first signs of memory problems

Thomson Reuters with files from the Associated Press

شارك هذا الموضوع:

  • فيس بوك
  • X

معجب بهذه:

إعجاب تحميل...

مرتبط

ShareTweetSend
Previous Post

حكومة كيبيك توضح أنها تريد مهاجرين فرنكوفونيين أو ’’فرنكوتروبيين‘‘ بنسبة 100%

Next Post

Man in life-threatening condition after shooting in Toronto’s west end

Duha Faris Al-Serdar

Duha Faris Al-Serdar

Next Post
Man in life-threatening condition after shooting in Toronto’s west end

Man in life-threatening condition after shooting in Toronto's west end

اترك تعليقاً إلغاء الرد

لن يتم نشر عنوان بريدك الإلكتروني. الحقول الإلزامية مشار إليها بـ *

No Result
View All Result

أحدث المقالات

  • أفتتاح نصب تذكاري للمهاجر اللبناني في هاليفاكس
  • زيارة وفد الجمعيات الكلدانية إلى محافظ وينزر لتعزيز التعاون المجتمعي وبحضور السيد الاستاذ غسان فؤاد ساكا
  • أنعقاد مؤتمر القمة العربية في العاصمة بغداد
  • أجتماع مجموعة السبع في أوتاوا
  • تعيين وزير الهجرة الكندية الجديدة من أصول لبنانية السيدة لينا متلج دياب

أحدث التعليقات

  • y على Why Switzerland built a 2-kilometer-long train
  • cropping على When it comes to their hair, Black women face a difficult choice
  • mentality على Trudeau announces more Russian sanctions, supports for Ukraine at Winnipeg congress
  • IBTISAM على بواليافر زعيماً جديداً للمحافظين وشاريه يدعو لرصّ الصفوف
  • Faris Al-Serdar على عمدة وندزور يكرم غسان ساكا

الأرشيف

  • مايو 2025
  • أبريل 2025
  • مارس 2025
  • فبراير 2025
  • يناير 2025
  • ديسمبر 2024
  • نوفمبر 2024
  • أكتوبر 2024
  • سبتمبر 2024
  • أغسطس 2024
  • يوليو 2024
  • يونيو 2024
  • مايو 2024
  • أبريل 2024
  • مارس 2024
  • فبراير 2024
  • يناير 2024
  • ديسمبر 2023
  • نوفمبر 2023
  • أكتوبر 2023
  • سبتمبر 2023
  • أغسطس 2023
  • يوليو 2023
  • يونيو 2023
  • مايو 2023
  • أبريل 2023
  • مارس 2023
  • فبراير 2023
  • يناير 2023
  • ديسمبر 2022
  • نوفمبر 2022
  • أكتوبر 2022
  • سبتمبر 2022
  • أغسطس 2022
  • يوليو 2022
  • يونيو 2022
  • مايو 2022
  • أبريل 2022
  • مارس 2022
  • فبراير 2022
  • يناير 2022
  • نوفمبر 2021
  • أكتوبر 2021
  • أغسطس 2021
  • يوليو 2021
  • مايو 2021
  • أبريل 2021
  • مارس 2021
  • فبراير 2021
  • يناير 2021

تصنيفات

  • Canadian News
  • Culture and Art
  • English
  • Health
  • Iraqi News
  • Lifestyle
  • Organization News
  • WORLD NEWS
  • أخبار العالم
  • أخبار المنظمة
  • اخبار العراق
  • اقتصاد
  • الأخبار الكندية
  • السياسة
  • تكنولوجيا
  • ثقافة و فن
  • حول العالم
  • عالم الصحة
  • عراقيات
  • غير مصنف
  • كلمة العدد
  • لايف ستايل
  • مقالات
  • منوعة

منوعات

  • تسجيل الدخول
  • خلاصات Feed الإدخالات
  • خلاصة التعليقات
  • WordPress.org

الاقسام

  • Canadian News
  • Culture and Art
  • English
  • Health
  • Iraqi News
  • Lifestyle
  • Organization News
  • WORLD NEWS
  • أخبار العالم
  • أخبار المنظمة
  • اخبار العراق
  • اقتصاد
  • الأخبار الكندية
  • السياسة
  • تكنولوجيا
  • ثقافة و فن
  • حول العالم
  • عالم الصحة
  • عراقيات
  • غير مصنف
  • كلمة العدد
  • لايف ستايل
  • مقالات
  • منوعة

الكلمات

arabic Breaking News downtown mission Face Masks Free happines icgo Masks News الأستاذ الياس طبرة الاستاذ الياس طبرة رحمن خضيرعباس هادي المهدي
  • الرئيسية
  • جريدة السفير
  • من نحن
  • الأتصال بنا
  • لايف ستايل
  • Lifestyle
  • EN
  • AR

©الحقوق المحفوظة لـ جريدة السفير 2021

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • الرئيسية
  • جريدة السفير
  • من نحن
  • الأتصال بنا
  • لايف ستايل
    • عراقيات
    • تكنولوجيا
    • مقالات
    • عالم الصحة
    • حول العالم
    • السياسة
    • كلمة العدد
    • ثقافة و فن
    • أخبار العالم
    • منوعة
  • Lifestyle
    • Culture and Art
    • WORLD NEWS
    • Health
    • Iraqi News
    • Organization News
    • Canadian News
  • EN
  • AR

©الحقوق المحفوظة لـ جريدة السفير 2021

The Ambassador Newspaper uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
%d